GE HealthCare Technologies Inc (GEHC): AI Imaging Surge, Intelerad Deal and 2026 Stock Forecasts

Updated December 7, 2025

GE HealthCare Technologies Inc (Nasdaq: GEHC) is closing out 2025 with a flurry of announcements that signal an aggressive pivot toward AI-powered imaging, cloud software and long-term clinical alliances. From a $2.3 billion deal to acquire imaging software specialist Intelerad, to new NVIDIA-powered scanners and multi-year partnerships with the Mayo Clinic and the University of Rochester Medical Center, the company is trying to redefine itself as a digital-first medtech platform as it heads into 2026. ^[1]

At the same time, GE HealthCare has delivered better‑than‑expected third‑quarter earnings, raised its 2025 profit outlook and attracted steady institutional interest, even as analysts’ stock price targets now imply only modest upside from current levels. ^[2]

Company snapshot: GE HealthCare in 2025

Spun out of General Electric in early 2023, GE HealthCare operates four primary segments: Imaging, Ultrasound, Patient Care Solutions and Pharmaceutical Diagnostics, selling hardware, software and services for diagnosis, treatment and patient monitoring worldwide. ^[3]

As of the latest close, GEHC shares trade around $85.46, giving the company a market capitalization of roughly $39 billion and placing it firmly in large‑cap medtech territory. ^[4] The stock has moved in a wide 52‑week range between about $57.65 and $94.80, reflecting shifting sentiment on hospital capital spending, China exposure and the broader rotation into AI‑linked names. ^[5]

Institutional investors remain deeply involved: funds and hedge funds own more than 80% of the float. Invesco recently trimmed its GEHC stake slightly in Q2 2025 but still owns around 1.73% of the company; Guggenheim Capital, by contrast, boosted its holdings by more than 20% over the same period. ^[6]

AI takes center stage: RSNA 2025 and NVIDIA‑powered imaging

The Radiological Society of North America (RSNA) 2025 meeting in Chicago has effectively become GE HealthCare’s AI showcase.

New MRI and CT platforms

At RSNA, GE HealthCare unveiled Signa One, its latest MRI platform designed to weave AI into the entire workflow — from pre‑scan planning and patient positioning to image acquisition and reading. A live camera feed helps position patients and synchronizes the scanner with breathing motion to reduce artifacts and improve image clarity. ^[7]

The Signa One ecosystem will initially power two new scanners:

Signa Bolt, a wide‑bore 3‑Tesla system for advanced diagnostics and research
Signa Sprint, a 1.5‑Tesla MRI that uses a “ventless” design and a sealed‑helium magnet said to require only about 1% of the helium used in traditional systems, helping hospitals manage cost and supply risk ^[8]

GE has also moved its Photonova Spectra photon‑counting CT system into U.S. regulatory review, betting that higher‑resolution spectral imaging and AI‑enhanced reconstruction will be key differentiators in oncology and cardiology. ^[9]

NVIDIA inside: accelerating scans and reconstruction

On December 2, GE HealthCare formally announced a suite of advanced imaging solutions powered by NVIDIA technology, integrating GPU acceleration into MRI, CT and ultrasound systems. ^[10]

Key systems highlighted in recent coverage include:

Vivid Pioneer, an ultra‑premium cardiovascular ultrasound platform that uses dual NVIDIA GPUs to speed image reconstruction, AI‑based quantification and high‑end visualization for complex heart exams ^[11]
New MRI and CT platforms that leverage NVIDIA GPUs for real‑time image enhancement, faster scan times and AI‑based workflow tools, with an emphasis on reducing repeat exams and shortening patient time in the scanner ^[12]

From an investment and competitive‑strategy perspective, the NVIDIA tie‑up signals that GE HealthCare is intent on matching, or beating, rivals like Philips and Siemens Healthineers in end‑to‑end AI imaging platforms rather than offering isolated algorithms. ^[13]

Imaging 360: AI in the radiology command center

Hardware is only half the story. GE HealthCare is also pushing Imaging 360, its cloud‑based radiology operations platform, as the nerve center of AI‑enabled imaging.

At RSNA 2025, the company rolled out AI‑enhanced Imaging 360 features designed to: ^[14]

Aggregate data across scanners, sites and modalities into one “command center” view
Automatically surface bottlenecks in scheduling, room utilization and technologist workloads
Use machine‑learning models to flag outliers in exam times or protocols and suggest optimization
Provide remote collaboration and scan‑assist tools (via Imaging 360 Remote/nCommand) to help less‑experienced technologists handle complex studies

Independent coverage notes that the AI upgrade aims to automate time‑consuming manual analysis and highlight actionable operational insights that were previously buried in spreadsheets and siloed PACS systems. ^[15]

Imaging 360 is strategically important because it cements GE’s move from one‑off equipment sales toward recurring cloud and software revenue, a theme that also shows up in the Intelerad acquisition and care‑alliance deals.

Strategic alliances: URMC and Mayo Clinic shape oncology and system‑wide upgrades

Seven‑year Care Alliance with University of Rochester Medical Center

On December 3, GE HealthCare announced a seven‑year Care Alliance with the University of Rochester Medical Center (URMC) in New York. ^[16]

According to GE and independent summaries, the alliance will: ^[17]

Upgrade UR Medicine’s imaging fleet across MRI, CT, PET/CT, SPECT/CT and ultrasound
Expand precision medicine capabilities, including advanced visualization and molecular imaging
Standardize patient monitoring and connected devices system‑wide
Establish an imaging “center of excellence” within URMC’s Imaging Sciences department

For GE HealthCare, the deal provides a multi‑year showcase site for its latest imaging, monitoring and operations platforms — effectively a living reference customer for other health systems considering similar enterprise‑scale partnerships.

GEMINI‑RT with Mayo Clinic: digital twins for radiation therapy

In oncology, GE HealthCare and Mayo Clinic have unveiled GEMINI‑RT, a joint research and innovation initiative focused on personalized radiation therapy. ^[18]

Across GE and third‑party reports, GEMINI‑RT aims to:

Build digital twin models of individual patients by linking diagnostic imaging, treatment planning and dose‑delivery data
Use AI to automate and optimize treatment plans, helping maximize tumor dose while minimizing exposure to healthy organs
Apply multi‑modal data (imaging, clinical records, sensors) to improve prediction of treatment responses and long‑term outcomes

The initiative extends a longstanding collaboration between the two organizations and positions GE HealthCare as a core technology partner in AI‑driven oncology workflows, not just as an equipment vendor.

Intelerad acquisition: a $2.3 billion bet on outpatient and cloud imaging

On November 20, GE HealthCare announced a deal to acquire Montreal‑based Intelerad for $2.3 billion in cash. ^[19]

Intelerad is a major provider of cloud‑based enterprise imaging software used heavily by outpatient imaging centers and radiology groups. The acquisition is designed to: ^[20]

Give GE HealthCare deeper access to the fast‑growing outpatient enterprise imaging market, which the company pegs as a “$2 billion‑plus” global opportunity
Expand GE’s software‑as‑a‑service (SaaS) footprint and recurring revenue base
Offer a natural home for GE’s own AI imaging algorithms, with Intelerad’s platform serving as the orchestration layer across multiple vendors and sites

Analysts quoted by Reuters characterized the deal as a strategic tuck‑in acquisition within GE HealthCare’s core domain, noting that Intelerad’s low double‑digit revenue growth should help lift GEHC’s top line and margins. The company expects the transaction to be immediately accretive to revenue growth and margins and to generate a high single‑digit return on invested capital by year five, with Intelerad forecast to deliver around $270 million in revenue in its first full year post‑closing. ^[21]

The transaction is slated to close in the first half of 2026, subject to regulatory approvals. ^[22]

Earnings check: Q3 2025 results and updated 2025 guidance

GE HealthCare’s latest reported quarter (Q3 2025, announced October 29) gives investors a snapshot of how these strategic moves sit on top of the company’s financials.

Top line and segments

For Q3 2025, GE HealthCare reported: ^[23]

Revenue of about $5.14 billion, slightly above analyst estimates (~$5.08 billion) and up roughly mid‑single digits year on year
Imaging devices revenue of about $2.35 billion, its largest segment, up 5%
A 3% sales decline in China to roughly $547 million, reflecting ongoing impacts from anti‑corruption crackdowns and slower economic stimulus

Net income attributable to GE HealthCare was around $446 million, down from roughly $470 million a year earlier, primarily due to tariff headwinds and cost pressures. ^[24]

Profitability and tariffs

On an adjusted basis, EPS came in at $1.07, beating consensus estimates of about $1.05 per share but down modestly versus the prior year. ^[25]

Driven by strong demand in the United States and the EMEA region, the company raised its 2025 adjusted profit forecast to a range of $4.51–$4.63 per share, lifting the midpoint by four cents from its earlier guidance of $4.43–$4.63. ^[26]

Management still expects roughly $265 million of tariff‑related impact in 2025 — equivalent to about $0.45 of EPS — tied to the Trump administration’s tariffs on India and certain metals, but now factoring in more recent trade measures on copper, steel and aluminum derivatives. ^[27]

MarketBeat’s summary of the quarter notes that revenue grew around 5.8% year over year, with a net margin near 11% and return on equity above 22%, underscoring a solid underlying profitability profile despite macro headwinds. ^[28]

GEHC stock today: valuation, analyst ratings and forecasts

Current trading levels and valuation

Recent MarketBeat data show GE HealthCare trading at: ^[29]

Price: about $85.46 per share
Market capitalization: around $38.9 billion
Trailing P/E: about 17.7
PEG ratio: roughly 3.5
Dividend yield: ~0.2%, based on a quarterly dividend of $0.035 per share

These metrics place GEHC in the mid‑teens earnings multiple range, somewhat typical for high‑quality, large‑cap medtech names with mid‑single‑digit growth and margin expansion potential.

Street view: Moderate Buy with limited near‑term upside

According to MarketBeat, 12 Wall Street analysts currently cover GE HealthCare, producing a “Moderate Buy” consensus rating: six rate the stock a Buy and six rate it a Hold. The average 12‑month price target is about $86.45, with estimates ranging from roughly $73 to $103 per share. Based on recent trading levels, that implies only around 1% upside in the base case. ^[30]

A separate aggregation from StocksGuide, drawing on around 23 analysts, puts the average target price slightly higher at about $88.74, suggesting low‑to‑mid single‑digit upside and a clear skew toward Buy recommendations (roughly two‑thirds Buy, one‑third Hold, virtually no Sell ratings). ^[31]

Recent broker moves include: ^[32]

Stifel Nicolaus reiterating a Buy rating and a $90 price target following RSNA 2025, citing improved visibility after the company’s AI imaging updates
Evercore ISI lifting its target from $88 to $92 with an “outperform” rating
Morgan Stanley raising its target from $74 to $80, maintaining an “equal weight” stance

Collectively, these calls suggest that while valuation is no longer undemanding, the Street sees room for incremental upside if GE HealthCare executes on its AI, software and outpatient‑imaging strategy.

Revenue, margin and EPS forecasts

Consensus forecasts compiled by StocksGuide point to a gradual but steady growth trajectory: ^[33]

Revenue: Analysts, on average, expect sales to rise from roughly $19.7 billion in 2024 to about $20.9 billion in 2025 (mid‑single‑digit growth), with continued low‑to‑mid single‑digit increases through 2029.
EBITDA: Forecasts imply EBITDA climbing from around $3.2 billion in 2024 to roughly $3.7 billion in 2025, with margins improving from the mid‑16% range to around 17.5–18% mid‑decade.
Net margin and EPS: Net margin is projected to hover near 10% in 2025 and trend into the low‑teens by the late 2020s. Average EPS estimates cluster around $4.6 for 2025, slightly below 2024 but then rising in subsequent years as margins expand and interest costs moderate.

These are, of course, directional scenarios rather than guarantees, but they frame how the market currently models GEHC’s medium‑term earnings power.

Capital structure and credit profile

In fixed‑income markets, S&P Global Ratings has rated GE HealthCare Technologies Inc.’s proposed senior unsecured notes ‘BBB’, placing them in the investment‑grade category and signaling moderate credit risk consistent with a large, diversified medtech issuer. ^[34]

GE HealthCare’s balance sheet, as reported in recent filings and summarized by MarketBeat, shows a debt‑to‑equity ratio below 1x and liquidity ratios (current and quick ratios near or just under 1x) that are typical for a capital‑equipment‑heavy healthcare company. ^[35]

Key themes and risks for the 2026 outlook

Growth drivers

AI and workflow platforms
- NVIDIA‑powered scanners, Signa One, Photonova Spectra and Imaging 360’s AI enhancements collectively position GE HealthCare as a full‑stack imaging and informatics provider rather than a hardware seller. ^[36]
Cloud and recurring revenue
- The Intelerad acquisition, Imaging 360 and CareIntellect‑type offerings accelerate the pivot toward SaaS and subscription models, which generally command higher multiples and stickier customer relationships than one‑time equipment sales. ^[37]
Flagship alliances and reference sites
- Long‑term collaborations with URMC and Mayo Clinic give GE HealthCare visible, high‑prestige venues to demonstrate integrated imaging, AI and oncology solutions — potentially aiding future enterprise deals with other systems. ^[38]
Demographic tailwinds
- Aging populations and rising chronic disease prevalence continue to support structural demand for imaging, monitoring and minimally invasive procedures, a backdrop that benefits all major medtech players, including GEHC.

Risk factors

Trade and tariff exposure
- Management’s estimate of a $265 million tariff headwind in 2025 underscores sensitivity to trade policy. A more adverse tariff environment or further expansion of metal and country‑specific duties could pressure margins. ^[39]
China and emerging‑market volatility
- Q3’s 3% sales decline in China, tied to anti‑corruption measures and stimulus delays, highlights regional risk. Longer‑lasting disruption could offset growth in other geographies. ^[40]
Integration risk around Intelerad
- While analysts largely view the Intelerad deal as strategically sound, integrating a sizable SaaS business into a historically equipment‑centric organization always carries execution risk, especially around culture, product roadmaps and sales force alignment. ^[41]
Competitive intensity
- Siemens Healthineers and Philips are also investing heavily in AI‑forward imaging platforms and cloud operations suites, ensuring that price and innovation pressure will remain high. RSNA 2025 coverage makes clear that all three are targeting “end‑to‑end” AI workflows, not just niche tools. ^[42]
Valuation and expectations
- With the stock already trading close to the average 12‑month target and many growth initiatives still in early stages, upside may depend on GE HealthCare outperforming current consensus on margins or growth, or on investors re‑rating AI‑heavy medtech assets more broadly. ^[43]

Bottom line: What today’s news means for GE HealthCare

As of December 7, 2025, GE HealthCare Technologies Inc sits at an inflection point:

The product and partnership pipeline is skewed heavily toward AI‑driven imaging, cloud‑based operations and personalized oncology — themes that align with where hospitals and health systems are directing capital. ^[44]
The Intelerad acquisition and URMC/Mayo alliances deepen the company’s integration into clinical workflows, potentially lifting switching costs and recurring revenue over time. ^[45]
Financially, GE HealthCare is delivering steady growth and margin resilience, with a raised 2025 EPS outlook and investment‑grade credit, yet consensus forecasts and price targets suggest markets are already pricing in much of that stability. ^[46]

For healthcare providers, these developments mean more tightly integrated imaging and oncology ecosystems. For investors, they frame GEHC as a large‑cap medtech name where the AI and cloud story is becoming more tangible, but where future returns will depend on the company’s ability to execute on integration, global growth and ongoing innovation.

This article is for informational purposes only and does not constitute investment advice. Investors should conduct their own research or consult a qualified financial advisor before making investment decisions.